UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Conformational Changes Induced by the A21G Flemish Mutation in the Amyloid Precursor Protein Lead to Increased Aβ Production

Structure (London), 2014-03, Vol.22 (3), p.387-396

2014

Volltextzugriff (PDF)

What is the role of amyloid precursor protein dimerization?

Cell adhesion & migration, 2010-04, Vol.4 (2), p.268-272

2010

Volltextzugriff (PDF)

Amyloidogenic Processing but Not Amyloid Precursor Protein (APP) Intracellular C-terminal Domain Production Requires a Precisely Oriented APP Dimer Assembled by Transmembrane GXXXG Motifs

The Journal of biological chemistry, 2008-03, Vol.283 (12), p.7733-7744

2008

Volltextzugriff (PDF)

Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor

Blood, 2010-02, Vol.115 (5), p.1037-1048

2010

Volltextzugriff (PDF)

Phosphorylation of APP695 at Thr668 decreases γ-cleavage and extracellular Aβ

Biochemical and biophysical research communications, 2007-06, Vol.357 (4), p.1004-1010

2007

Volltextzugriff (PDF)

Phosphorylation of APP695 at Thr668 decreases gamma-cleavage and extracellular Abeta

Biochemical and biophysical research communications, 2007-06, Vol.357 (4), p.1004

2007

Volltextzugriff (PDF)

P2-054: Lack of phosphorylation of the amyloid precursor protein on Thr668 residue increases the gamma-cleavage of the protein

Alzheimer's & dementia, 2006-07, Vol.2 (3), p.S248-S248

2006

Volltextzugriff (PDF)

P2‐142: Analysis of the dimerization and metabolism of different APP isoforms

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_10), p.P303-P303

2009

Volltextzugriff (PDF)

Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. VOLUME 283 (2008) PAGES 7733-7744

The Journal of biological chemistry, 2008-05, Vol.283 (18), p.12680-12680

2008

Volltextzugriff (PDF)

Amyloidogenic Processing but not AICD Production Requires a Precisely Oriented APP Dimer Assembled by Transmembrane GXXXG Motifs

The Journal of biological chemistry, 2008-01, Vol.283 (12), p.7733-7744

2008

Volltextzugriff (PDF)

O1‐05‐01: Structural requirements for APP processing by γ‐secretase

Alzheimer's & dementia, 2009-07, Vol.5 (4S_Part_3), p.P87-P87

2009

Volltextzugriff (PDF)

Structural requirements for APP processing by γ-secretase

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P87-P87

2009

Volltextzugriff (PDF)

Analysis of the dimerization and metabolism of different APP isoforms

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P303-P303

2009

Volltextzugriff (PDF)

P1-425: Dimerization and orientation of the transmembrane domain control APP amyloidogenic processing

Alzheimer's & dementia, 2008-07, Vol.4 (4), p.T344-T344

2008

Volltextzugriff (PDF)

Analysis of the progression of JAK2 V617F positive myeloproliferative neoplasms by single-nucleotide polymorphism array does not reveal a strong chromosomal instability

Cancer genetics and cytogenetics, 2009-07, Vol.192 (2), p.102-104

2009

Volltextzugriff (PDF)

The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease

American journal of obstetrics and gynecology, 2022-08, Vol.227 (2), p.250.e1-250.e8

2022

Volltextzugriff (PDF)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Muscle & nerve, 2019-07, Vol.60 (1), p.14-24

2019

Volltextzugriff (PDF)

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Neurology, 2021-01, Vol.96 (4), p.e610

2021

Volltextzugriff (PDF)

The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease

JMIR research protocols, 2017-09, Vol.6 (9), p.e178-e178

2017

Volltextzugriff (PDF)

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

Journal of neurology, 2020-07, Vol.267 (7), p.1991-2001

2020

Volltextzugriff (PDF)

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Quality of life research, 2019-08, Vol.28 (8), p.2247-2255

2019

Volltextzugriff (PDF)

Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study

Muscle & nerve, 2021-12, Vol.64 (6), p.662-669

2021

Volltextzugriff (PDF)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis

Quality of life research, 2019-08, Vol.28 (8), p.2255-2255

2019

Volltextzugriff (PDF)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Annals of clinical and translational neurology, 2020-08, Vol.7 (8), p.1327-1339

2020

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(10)
Activities Of Daily Living
(5)
Animals
(5)
Clinical Neurology
(5)
Middle Aged
(5)
Monoclonal Antibodies
(5)
Myasthenia Gravis
(5)
Myasthenia Gravis - Drug Therapy
(5)
Neurosciences & Neurology
(5)
Amyloid Beta-Protein Precursor - Metabolism
(4)
Eculizumab
(4)
Female
(4)
Male
(4)
Neurology
(4)
Neurosciences
(4)
Patients
(4)
Quality Of Life
(4)
Adult
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Conformational Changes Induced by the A21G Flemish Mutation in the Amyloid Precursor Protein Lead to Increased Aβ Production

What is the role of amyloid precursor protein dimerization?

Amyloidogenic Processing but Not Amyloid Precursor Protein (APP) Intracellular C-terminal Domain Production Requires a Precisely Oriented APP Dimer Assembled by Transmembrane GXXXG Motifs

Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor

Phosphorylation of APP695 at Thr668 decreases γ-cleavage and extracellular Aβ

Phosphorylation of APP695 at Thr668 decreases gamma-cleavage and extracellular Abeta

P2-054: Lack of phosphorylation of the amyloid precursor protein on Thr668 residue increases the gamma-cleavage of the protein

P2‐142: Analysis of the dimerization and metabolism of different APP isoforms

Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. VOLUME 283 (2008) PAGES 7733-7744

Amyloidogenic Processing but not AICD Production Requires a Precisely Oriented APP Dimer Assembled by Transmembrane GXXXG Motifs

O1‐05‐01: Structural requirements for APP processing by γ‐secretase

Structural requirements for APP processing by γ-secretase

Analysis of the dimerization and metabolism of different APP isoforms

P1-425: Dimerization and orientation of the transmembrane domain control APP amyloidogenic processing

Analysis of the progression of JAK2 V617F positive myeloproliferative neoplasms by single-nucleotide polymorphism array does not reveal a strong chromosomal instability

The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Suchergebnisse filtern